Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood biomarkers may let ICU patients stop antifungals earlier

NCT ID NCT03538912

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using blood biomarkers (beta-D-glucan and mannan) can help doctors safely stop antifungal drugs earlier in critically ill patients suspected of a fungal infection. 192 ICU patients were randomly assigned to either a biomarker-guided strategy or standard care. The goal was to see if the biomarker approach could reduce unnecessary antifungal use without increasing the risk of death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
biomarker-guided strategy (blood tests for fungal markers)
What this could lead to
If successful, this approach could reduce unnecessary antifungal use in ICU patients, lowering side effects and costs without increasing deaths.
What could go wrong
This is a completed trial with 192 patients, so results are available but may not apply to all ICU settings. The biomarker strategy might not be as safe in patients with weak immune systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

192 people

The number who actually took part.

Started

Jun 2018

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient older than 18 years * Who require EAT for the first time in the ICU (this treatment is prescribed based on the presence of risk factors and clinical suspicion of ICI) * With an expected ICU length of stay of at least 6 days after EAT initiation * Informed written consent Exclusion Criteria: * Neutropenia (neutrophil count \<500 cells /µL) * Active malignant hemopathy * Bone marrow transplantation in the last 6 months * Polyvalent immunoglobulins in the past months * Documented ICI in the past 3 months * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive candidiasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

candidiasis, invasive disseminated candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive candidiasis

Contacts and locations

Locations

  • CH ARRAS

    Arras, France

  • CH Dunkerque

    Dunkirk, France

  • CH Roubaix

    Roubaix, France

  • CH de DOUAI

    Douai, France

  • CHU de Rouen

    Rouen, France

  • Centre Hospitalier Dr Schaffner

    Lens, France

  • Centre hospitalier de valenciennes

    Valenciennes, France

  • Ch Dr.Schaffner de Lens

    Lens, France

  • Ch Tourcoing

    Tourcoing, France

  • Hôpital Roger Salengro, CHU

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.